Amyloidosis trials in Brazil

In Brazil 11 Also abroad 184

11 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
Where
Belo Horizonte, Campinas, Niterói, Ribeirão Preto, Rio de Janeiro, Salvador, São Paulo
Age
18 years to 90 years
People
1,200 worldwide
Run by
Intellia Therapeutics
See details and how to joinNCT06128629 · EU 2023-507220-23-00
Phase 2Not yet taking people in Brazil
Effect of Trimetazidine on Coronary Flow in Transthyretin Cardiac Amyloidosis
Where
São Paulo
Age
18 years and over
People
20
Run by
Fábio Fernandes
See details and how to joinNCT07836699
Phase 3Enrolling by invitation
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Where
Ribeirão Preto, Rio de Janeiro, São Paulo
Age
18 years and over
People
700 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT06679946
Phase 3Taking people
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Where
Belo Horizonte, Brasília, Campinas, Caxias do Sul, Curitiba, Porto Alegre, Recife - PE, Ribeirão Preto, Salvador, São Paulo, Uberlândia
Age
18 years and over
People
1,280 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT07207811
Phase 3Taking people
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Where
Belo Horizonte, Campinas, Porto Alegre, Recife, Ribeirão Preto, Rio de Janeiro, Salvador, São Paulo
Age
18 years to 85 years
People
1,750 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT07052903 · EU 2024-519917-72-00
No phaseTaking people
ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
Where
Salvador, São Paulo
People
1,500 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT04561518
Phase 3Taking people
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
Where
Ribeirão Preto, Rio de Janeiro, Salvador, São Paulo
Age
18 years to 85 years
People
125 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT07223203 · EU 2025-522544-40-00
Phase 3Not yet taking people in Brazil
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
Where
Campinas, Fortaleza, Porto Alegre, Ribeirão Preto, Rio de Janeiro, São Paulo
People
1,180 worldwide
Run by
Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07789483 · EU 2026-526755-57-00
Phase 3Taking people
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Where
Campinas, Cerqueira César, Ribeirão Preto, Salvador
Age
18 years to 75 years
People
587 worldwide
Run by
Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT06563895 · EU 2024-513547-82-00
Phase 3Enrolling by invitation
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Where
Porto Alegre, Ribeirão Preto, São Paulo
Age
18 years and over
People
1,400 worldwide
Run by
Ionis Pharmaceuticals, Inc.
See details and how to joinNCT05667493
No phaseTaking people
ATTR Amyloid Cardiomyopathy: Characterization of Extracellular Vesicles as Potential Disease Stratifiers and Prognostic Biomarkers
Where
São Paulo
Age
18 years and over
People
70
Run by
University of Sao Paulo General Hospital
See details and how to joinNCT07314268